歡迎來到北京鍵凱科技股份有限公司官方網站!

>
>
Y-shape PEG NHS Ester
瀏覽量:
產品名稱:

Y-shape PEG NHS Ester

產品代號:
Y-NHS-40K
產品純度:
≥ 95%
分子量:
2000 Da, 5000 Da, 10000 Da等
產品編號:
A0001
沒有此類產品
產品描述

  Y型NHS是JenKem的專利產品,具有2個PEG鏈和一個活性酯基因,可以用來生產蛋白或其他生物分子中的賴氨酸上的氨基進行反應。Y-NHS可以在PH=7-8的緩沖液中在較短的時間內與NH2進行聚乙二醇化。由于Y-NHS具有獨特的空間結構使它更具有選擇性。

  鍵凱科技提供Y型分子量40K的1克、10克和100克包裝的產品。

  鍵凱科技提供分裝服務,需要收取分裝費用,如果您需要分裝為其他規格請與我們聯系。

  鍵凱科技同時提供其他分子量的Y型衍生物產品,如你需要請與我司[email protected]聯系。

  鍵凱科技提供大批量生產產品及GMP級別產品,如需報價請與我們聯系。

References:

1. AlQahtani, A.D., et al., Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment, European Journal of Pharmaceutical Sciences, 2019, 127, P. 79-91.

2. Haruta, K., et al., A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers, Nucleic acid therapeutics, 2017, 27(1):36-44.

3. Guo, L., et al., Application Instructions for Y-NHS-40K for Amine PEGylation, click link.

4. Masao, H., et al., Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys, Nucleic Acid Therapeutics, 2015.

5. Winship, A.L., Interleukin-11 alters placentation and causes preeclampsia features in mice, Proc Natl Acad Sci U S A., 2015, 112(52):15928-33.

6. Risitano, A.M., et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria, Blood Mar, 2014, 123 (13) 2094-2101.

7. Roccaro, Aldo M. et al., SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy, Cell Reports, 2014, 9 (1), p: 118 – 128.

8. Stefan, N., et al., Novel Prodrug-Like Fusion Toxin with Protease-Sensitive Bioorthogonal PEGylation for Tumor Targeting, Bioconjugate chemistry, 2014, 25.12: 2144-2156.

9. Ashokan, A., et al., Multifunctional calcium phosphate nano-contrast agent for combined nuclear, magnetic and near-infrared in vivo imaging. Biomaterials, 2013, 34(29): p. 7143-7157.

10. Khan, M.A., et al., Targeting complement component 5a promotes vascular integrity and limits airway remodeling, PNAS, 2013, 110(15) p:6061-6066.

11. Dai, C.Y., et al., Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application, Science China Life Sciences, 2013, 56.1 : 51-58.

12. Dai, C.Y., et al., Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma, Science China Life Sci, 2011, 54(2): 128–138.

13. Menkhorst, E., et al., Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated NonTarget Effects on Bone in Mice, PLoS ONE, 2011, 6 (5) e19665.

14. Cai, Y., et al., Separation of exenatide analogue mono-PEGylated with 40 kDA polyethylene glycol by cation exchange chromatography, Journal of Chromatography A, 2011, 1218:39, P. 6953-6960.

15. Wang, Y-J., et al., PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin, Journal of Controlled Release, 2010, 145:3, p. 306-313.

16. Marcus, Y., et al., Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin, Journal of Medicinal Chemistry, 2008, 51 (14), 4300-4305.

17. Wang, S., et al., Y-type polyethylene glycol modified G-CSF and preparation method and use thereof. Patent CN200780051378, 2007.

18. Zhou, W., et al., Interferon alpha 2a modified by polyethylene glycol, its synthesis process and application. Patent CN200780050541, 2007.

19. Zhou, W., et al., Interferon alpha 2b modified by polyethylene glycol, its synthesis process and application. Patent CN200780050542, 2007.

20. Zhou, W., et al., Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof. Patent CN200880009718, 2008.

未找到相應參數組,請于后臺屬性模板中添加
暫未實現,敬請期待
暫未實現,敬請期待
上一篇
下一篇
河北快3中奖规则奖金